CF
JSPR icon

Corebridge Financial’s Jasper Therapeutics JSPR Stock Holding History

Corebridge Financial’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,546
Closed -$23.8K – 1413
2025
Q1 		$23.8K Sell
5,546
-82
-1% -$546 ﹤0.01% 2881
2024
Q4 		$120K Sell
5,628
-425
-7% -$8.85K ﹤0.01% 2461
2024
Q3 		$114K Sell
6,053
-37
-0.6% -$737 ﹤0.01% 2555
2024
Q2 		$138K Buy
+6,090
New +$146K ﹤0.01% 2419

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Corebridge Financial's JSPR Position: Q2 2025 in Review

Corebridge Financial sold out of Jasper Therapeutics (JSPR) in Q2 2025, closing a stake of 5,546 shares — an estimated $23.8K sold.

Corebridge Financial first reported a position in JSPR in Q2 2024 and held it in 4 quarters. The position peaked at $138K in Q2 2024. 65 funds tracked by Wall St. Rank hold JSPR as of Q2 2025.

  • Corebridge Financial reported no remaining Jasper Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 5,546 Jasper Therapeutics shares in Q2 2025, an estimated $23.8K.
  • Corebridge Financial first reported a position in Jasper Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Jasper Therapeutics position peaked at $138K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.